Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 15 of 28 results for venetoclax

  1. Venetoclax for treating chronic lymphocytic leukaemia (TA796)

    Evidence-based recommendations on venetoclax (Venclyxto) for chronic lymphocytic leukaemia in adults.

    Technology appraisal guidance
    Published
    15 June 2022
    View recommendations

    Sections for TA796

  2. Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia (TA1119)

    Evidence-based recommendations on venetoclax (Venclyxto) with obinutuzumab (Gazyvaro) for untreated chronic lymphocytic leukaemia in adults.

    Technology appraisal guidance
    Published
    7 January 2026

    Sections for TA1119

  3. Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia (TA891)

    Evidence-based recommendations on ibrutinib (Imbruvica) with venetoclax (Venclyxto) for untreated chronic lymphocytic leukaemia in adults.

    Technology appraisal guidance
    Published
    31 May 2023
    View recommendations

    Sections for TA891

  4. Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia (TA561)

    Evidence-based recommendations on venetoclax (Venclyxto) with rituximab for previously treated chronic lymphocytic leukaemia in adults.

    Technology appraisal guidance
    Published
    27 February 2019
    View recommendations

    Sections for TA561

  5. Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (TA765)

    Evidence-based recommendations on venetoclax (Venclyxto) with azacitidine for untreated acute myeloid leukaemia in adults when intensive chemotherapy is unsuitable.

    Technology appraisal guidance
    Published
    2 February 2022
    View recommendations

    Sections for TA765

  6. Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (TA787)

    Evidence-based recommendations on venetoclax (Venclyxto) with low dose cytarabine for untreated acute myeloid leukaemia in adults when intensive chemotherapy is unsuitable.

    Technology appraisal guidance
    Published
    27 April 2022
    View recommendations

    Sections for TA787

  7. Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia [ID6156]

    Awaiting development Reference number: GID-TA11087 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Acalabrutinib and venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia [ID6232]

    In development Reference number: GID-TA11230 Expected publication date:  07 May 2026

    Technology appraisal guidance
    In development

  9. Pirtobrutinib with venetoclax and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6566]

    Awaiting development Reference number: GID-TA11748 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Decitabine–cedazuridine with venetoclax for treating acute myeloid leukaemia when intensive induction chemotherapy is unsuitable [ID6601]

    In development Reference number: GID-TA11765 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Pirtobrutinib for treating chronic lymphocytic leukaemia or small lymphocytic lymphoma after 1 or more BTK inhibitors [ID6269]

    In development Reference number: GID-TA11298 Expected publication date:  29 January 2026

    Technology appraisal guidance
    In development

  12. Zanubrutinib for treating chronic lymphocytic leukaemia (TA931)

    Evidence-based recommendations on zanubrutinib (Brukinsa) for treating chronic lymphocytic leukaemia in adults.

    Technology appraisal guidance
    Published
    22 November 2023
    View recommendations

    Sections for TA931

  13. Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation (TA979)

    Evidence-based recommendations on ivosidenib (Tibsovo) with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation.

    Technology appraisal guidance
    Published
    5 June 2024
    View recommendations

    Sections for TA979

  14. Decitabine–cedazuridine with venetoclax for treating acute myeloid leukaemia when intensive induction chemotherapy is unsuitable [ID6601]: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 11 February 2026.

    Technology appraisal guidance
    In consultation

  15. Acalabrutinib for treating chronic lymphocytic leukaemia (TA689)

    Evidence-based recommendations on acalabrutinib (Calquence) for treating chronic lymphocytic leukaemia in adults.

    Technology appraisal guidance
    Published
    21 April 2021
    View recommendations

    Sections for TA689